Clinical Trials Sponsored by Hameln Pharma GmbH

Total 340 results

Pari Pharma GmbH

Completed

Bioequivalence and Safety of Vantobra and TOBI in Healthy Subjects

Cystic Fibrosis

Germany
UCB Pharma GmbH

Completed

Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy (VICTOS)

Focal Epilepsy With and Without Secondary Generalization

Germany, Austria
UCB Pharma GmbH

Completed

Observation of Treatment With Certolizumab Pegol in Daily Practice (FasT)

Rheumatoid Arthritis

Germany
UCB Pharma GmbH

Completed

Change in Gastrointestinal Complaints After Switch From Oral Parkinson's Disease Treatment to Neupro® Transdermal Patch (NON-GI)

Idiopathic Parkinson's Disease

Germany
UCB Pharma GmbH

Completed

Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s Disease (NEUPAD)

Idiopathic Parkinson's Disease

Germany, Austria
UCB Pharma GmbH

Completed

Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug (VITOBA)

Epilepsies, Partial

Germany
CellAct Pharma GmbH
Mundipharma-EDO GmbH

Terminated

CAP7.1 for the Treatment of Advanced Stage, Therapy Refractory Lung and Biliary Tract Tumors (CAP7-1)

Advanced Endstage Solid Carcinomas in Adults

Germany
Ever Neuro Pharma GmbH
acromion GmbH

Completed

Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease (Combi)

Alzheimer Disease

Spain
Ever Neuro Pharma GmbH
VASCage GmbH

Terminated

IMPULSE - StIMulation of Brain Plasticity to Improve Upper Limb Recovery After StrokE (IMPULSE)

Chronic Stroke | Subacute Stroke

Austria
WiSP Wissenschaftlicher Service Pharma GmbH
Mundipharma Research GmbH & Co KG; Klinikum Leverkusen gGmbH; ribosepharm GmbH

Completed

Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

Germany
AIO-Studien-gGmbH
Amgen; WiSP Wissenschaftlicher Service Pharma GmbH

Completed

ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction (NEOPECX)

Stomach Neoplasms | Gastroesophageal Junction Neoplasms

Germany
Sumitomo Pharma Switzerland GmbH

Recruiting

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

Endometriosis | Uterine Fibroids

United States
Sumitomo Pharma Switzerland GmbH

Recruiting

A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX (OPTYX)

Prostate Cancer

United States
Dr. Falk Pharma GmbH

Recruiting

Norursodeoxycholic Acid vs. Placebo in NASH

Nonalcoholic Steatohepatitis

Austria
Sumitomo Pharma Switzerland GmbH

Active, not recruiting

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate Cancer

United States
Dr. Falk Pharma GmbH

Completed

Different Doses of ZED1227 vs. Placebo in NAFLD (NormaliZED)

NAFLD | Liver Fibrosis

Germany
Dr. Falk Pharma GmbH

Completed

Mesalazine Oral Suspension in Active Eosinophilic Esophagitis

Eosinophilic Esophagitis

Switzerland
Dr. Falk Pharma GmbH

Completed

Budesonide for Induction of Remission in Incomplete Microscopic Colitis

Incomplete Microscopic Colitis

Germany, Sweden
Dr. Falk Pharma GmbH

Terminated

Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone in Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis

France, Germany
Dr. Falk Pharma GmbH

Completed

Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis

Proctitis

Germany
Dr. Falk Pharma GmbH

Completed

Pharmacokinetic Investigation of UDCA in Bile and Serum

Healthy

Netherlands
Ever Neuro Pharma GmbH

Withdrawn

Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT) (DAT)

Alzheimer Disease

Austria
Dr. Falk Pharma GmbH

Terminated

Budesonide Foam Versus Placebo for Prevention of Acute Radiation Proctitis

Radiation Proctitis

Germany
Sumitomo Pharma Switzerland GmbH

Recruiting

Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring

Pregnancy Complications | Pregnancy Related | Pregnancy, High Risk

United States
Dr. Falk Pharma GmbH

Recruiting

Different Doses of Naronapride vs. Placebo in Gastroparesis (MOVE-IT)

Gastroparesis

Belgium
Sumitomo Pharma Switzerland GmbH

Recruiting

Congenital Athymia Patient Registry

Complete DiGeorge Anomaly | Complete DiGeorge Syndrome | Congenital Athymia

United States
Croma-Pharma GmbH
Hugel

Completed

Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines (H2H)

Frown Lines

United States, Austria, Canada
Dr. Falk Pharma GmbH

Completed

Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2) (PROTECT-2)

Ulcerative Colitis

Germany
Dr. Falk Pharma GmbH

Completed

Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

Germany
Dr. Falk Pharma GmbH

Completed

Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis

Autoimmune Hepatitis

Germany
Dr. Falk Pharma GmbH

Completed

Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in Acute Uncomplicated Diverticulitis

Uncomplicated Diverticulitis

Germany
Dr. Falk Pharma GmbH

Terminated

Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis

Diverticulitis

Germany
Dr. Falk Pharma GmbH

Terminated

Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis (PROTECT-1)

Ulcerative Colitis

Germany
Dr. Falk Pharma GmbH

Completed

Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis (NUC-3)

Primary Sclerosing Cholangitis

Austria, Germany, Norway
Dr. Falk Pharma GmbH

Completed

Efficacy and Safety Study of Budesonide to Treat Oral Chronic Graft vs Host Disease (cGvHD)

Oral Chronic Graft vs Host Disease

Germany, Israel
Dr. Falk Pharma GmbH

Completed

Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis

Eosinophilic Esophagitis

Germany
Sanol GmbH

Completed

A Double-blind, Double-dummy, Parallel, Active-controlled, Randomized Trial to Evaluate Efficacy & Safety in Anemia Subjects

Iron Deficiency Anemia

China
Dr. Falk Pharma GmbH

Completed

9 mg Budesonide Once Daily (OD) Versus 3 mg Budesonide Three Times Daily (TID) in Active Crohn's Disease

Crohn´s Disease

Germany
Dr. Falk Pharma GmbH

Completed

Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD)

Crohn's Disease

Germany
Dr. Falk Pharma GmbH

Completed

Budesonide Capsules vs. Mesalazine Granules vs. Placebo in Collagenous Colitis

Collagenous Colitis

Germany
Dr. Falk Pharma GmbH

Completed

Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC)

Colitis, Ulcerative

Germany
Dr. Falk Pharma GmbH

Completed

Preventing Postoperative Relapse in Crohn's Disease Patients at Risk: Azathioprine Versus Mesalazine

Crohn's Disease

Austria, Germany
Dr. Falk Pharma GmbH

Completed

Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)

Recurrence | Colitis, Ulcerative

Germany
Orphanetics Pharma Entwicklungs GmbH

Terminated

Long-Term Tetrahydrobiopterin Treatment in PKU Patients of 0-18 Years - Study on Phenylalanine Tolerance and Safety

Phenylalanine Hydroxylase Deficiencies
Sumitomo Pharma Switzerland GmbH

Not yet recruiting

MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy

Pregnancy Complications | Pregnancy Related | Pregnancy, High Risk
Dr. Falk Pharma GmbH

Recruiting

norUrsodeoxycholic Acid vs Placebo in PSC

Primary Sclerosing Cholangitis

Austria, Germany
Sumitomo Pharma Switzerland GmbH

Active, not recruiting

Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate (REPLACE-CV)

Prostate Cancer

United States
Mitsubishi Tanabe Pharma GmbH

Completed

Safety of Argatroban Infusion in Conduction Disturbances (SAICoDis)

Stable Coronary Artery Disease (CAD) | Unstable Angina (Troponin Negative)

Germany
Sumitomo Pharma Switzerland GmbH

Active, not recruiting

Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy (SERENE)

Contraception

United States, Puerto Rico
Dr. Falk Pharma GmbH

Completed

Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis (EOS-2)

Eosinophilic Esophagitis

Germany

3

Subscribe